Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirbanibulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 4/20 | 0.98 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.98 |
| ▸ | TUBB | P07437 | 6/20 | 0.98 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.98 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.98 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.98 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.98 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.98 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.98 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.98 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.98 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.98 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.98 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.98 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.98 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
| ▸ | LYN | P07948 | 1/20 | 0.98 |
| ▸ | BCR | P11274 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirbanibulin SCHEMBL1884803 | 1.00 | TUBB4A (0.98) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Tirbanibulin SCHEMBL1884806 | 1.00 | TUBB4A (0.98) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Tirbanibulin SCHEMBL153779 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Tirbanibulin SCHEMBL29386081 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Tirbanibulin SCHEMBL157019 | 0.95 | TUBB4A (0.92) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Tirbanibulin SCHEMBL29580902 | 0.95 | TUBB4A (0.92) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22567081 | 0.93 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27144723 | 0.91 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20780439 | 0.90 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL253925 | 0.90 | SRC (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114934-B1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2015-10-21 | — | — | EP | claimed |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATNX SPV LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20220160672-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-20210198202-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-01 | — | — | US | disclosed |
| EP-3777832-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Athenex, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-2217229-B1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATHENEX INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20190256468-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC | 2019-08-22 | — | — | US | disclosed |
| US-10323001-B2 | Compositions for modulating a kinase cascade and methods of use thereof | ATHENEX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2155681-B1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATHENEX INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2558085-B1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | ATHENEX INC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2217229-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Kinex Pharmaceuticals, LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2155681-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Kinex Pharmaceuticals, LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090318450-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2114934-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | Kinex Pharmaceuticals, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009051848-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008144045-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-11-20 | — | — | US | disclosed |
| WO-2008082637-A9 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082637-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | MAP3K4, MAP3K6, MAP3K3 | SRC 82/4885TUBB4A 2746/4885TUBB 2407/4885 |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | MAP3K2, MAP3K6, MAP3K4 | SRC 133/4885TUBB4A 1724/4885TUBB 2453/4885 |
| US-10323001-B2 | Compositions for modulating a kinase cascade and methods of use thereof | MAP3K2, MAP3K4, MAP3K5 | SRC 185/4885TUBB4A 1606/4885TUBB 2563/4885 |
| US-20220160672-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K6, MAP3K10 | SRC 35/4885TUBB4A 2153/4885TUBB 1787/4885 |
| US-20090318450-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | SRC 185/4885TUBB4A 1606/4885TUBB 2563/4885 |
| US-20190256468-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | SRC 185/4885TUBB4A 1606/4885TUBB 2563/4885 |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | SRC 185/4885TUBB4A 1606/4885TUBB 2563/4885 |
| US-20210198202-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | SRC 197/4885TUBB4A 1570/4885TUBB 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.